Andreas Greinacher

List of Publications by Year in Descending Order

472 papers	25,760 citations	84 h-index	145 g-index
514 ext. papers	30,873 ext. citations	7.6 avg, IF	7.44 L-index

#	Paper	IF	Citations
472	Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: Retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany.. *Lancet Regional Health - Europe, The*, **2022**, 12, 100270		7
471	Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines.. *Haematologica*, **2022**,	6.6	6
470	Ex vivo anticoagulants affect human blood platelet biomechanics with implications for high-throughput functional mechanophenotyping.. *Communications Biology*, **2022**, 5, 86	6.7	3
469	Vaccine-induced immune thrombotic thrombocytopenia (VITT) - update on diagnosis and management considering different resources: Response to Comment from Yamada et al.. *Journal of Thrombosis and Haemostasis*, **2022**, 20, 542-543	15.4	3
468	Most Anti-PF4 Antibodies in Vaccine-induced Immune Thrombotic Thrombocytopenia are transient.. *Blood*, **2022**,	2.2	3
467	Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT).. *Seminars in Hematology*, **2022**, 59, 97-107	4	2
466	Laboratory testing for VITT antibodies.. *Seminars in Hematology*, **2022**, 59, 80-88	4	2
465	-hemolysin of Staphylococcus aureus impairs thrombus formation.. *Journal of Thrombosis and Haemostasis*, **2022**,	15.4	1
464	Longitudinal Aspects of VITT.. *Seminars in Hematology*, **2022**, 59, 108-114	4	2
463	Divalent magnesium restores cytoskeletal storage lesions in cold-stored platelet concentrates.. *Scientific Reports*, **2022**, 12, 6229	4.9	0
462	Cytoskeleton Dependent Mobility Dynamics of FcRIIA Facilitates Platelet Haptotaxis and Capture of Opsonized Bacteria. *Cells*, **2022**, 11, 1615	7.9	
461	Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry.. *Neurological Research and Practice*, **2022**, 4, 16	3.2	0
460	Group B Streptococcal Hemolytic Pigment Impairs Platelet Function in a Two-Step Process. *Cells*, **2022**, 11, 1637	7.9	0
459	Reduced platelet forces underlie impaired hemostasis in mouse models of -related disease.. *Science Advances*, **2022**, 8, eabn2627	14.3	2
458	Heparin-Induced Thrombocytopenia **2022**, 187-205		1
457	Highly impaired platelet ultrastructure in two families with novel variants. *Platelets*, **2021**, 32, 492-497	3.6	
456	The COVID-19 vaccine ChAdOx1-S is not contaminated with sulfated glycosaminoglycans.. *Journal of Thrombosis and Haemostasis*, **2021**,	15.4	2

455	Multicentre evaluation of 5B9, a monoclonal anti-PF4/heparin IgG mimicking human HIT antibodies, as an internal quality control in HIT functional assays: Communication from the ISTH SSC Subcommittee on Platelet Immunology. *Journal of Thrombosis and Haemostasis*, **2021**,	15.4	3
454	Complicated Long Term Vaccine Induced Thrombotic Immune Thrombocytopenia-A Case Report. *Vaccines*, **2021**, 9,	5.3	11
453	The Deglycosylated Form of 1E12, a Monoclonal Anti-PF4 IgG, Strongly Inhibits Antibody-Triggered Cellular Activation in Vaccine-Induced Thrombotic Thrombocytopenia, and Is a Potential New Treatment for V *Blood*, **2021**, 138, 582-582	2.2	2
452	Heterogeneity of vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination and safety of second vaccination with BNT162b2. *Thrombosis and Haemostasis*, **2021**,	7	3
451	Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources. *Journal of Thrombosis and Haemostasis*, **2021**,	15.4	21
450	Blood Product Supply for a Helicopter Emergency Medical Service.. *Transfusion Medicine and Hemotherapy*, **2021**, 48, 332-341	4.2	1
449	GFHT proposals on the practical use of argatroban - With specifics regarding vaccine-induced immune thrombotic thrombocytopaenia (VITT). *Anaesthesia, Critical Care & Pain Medicine*, **2021** , 40, 100963	3	1
448	10 Years of Experience with the First Thawed Plasma Bank in Germany.. *Transfusion Medicine and Hemotherapy*, **2021**, 48, 350-357	4.2	0
447	Population-Based Analysis of the Impact of Demographics on the Current and Future Blood Supply in the Saarland. *Transfusion Medicine and Hemotherapy*, **2021**, 48, 175-182	4.2	0
446	COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 1294-1298	15.4	31
445	Proteomics: A Tool to Study Platelet Function. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
444	Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH. *Hamostaseologie*, **2021**, 41, 184-189	1.9	97
443	Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. *Journal of Neurology*, **2021**, 268, 4483-4485	5.5	19
442	Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. *Blood*, **2021**, 138, 299-303	2.2	60
441	A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination. *Blood*, **2021**, 137, 3656-3659	2.2	23
440	Platelets modulate T-cell activity. *Blood*, **2021**, 138, 358-360	2.2	1
439	PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia. *New England Journal of Medicine*, **2021**, 385, 376-378	59.2	49
438	Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *New England Journal of Medicine*, **2021**, 384, 2092-2101	59.2	940

437	Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia. *Chest*, **2021**, 159, 2417-2427	5.3	34
436	Heparin-induced thrombocytopenia: Construction of a pretest diagnostic score derived from the analysis of a prospective multinational database, with internal validation. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 1959-1972	15.4	6
435	The platelet proteasome and immunoproteasome are stable in buffy-coat derived platelet concentrates for up to 7 days. *Transfusion*, **2021**, 61, 2746-2755	2.9	0
434	A novel homozygous variant in 2 sisters with thrombocytopenia and severe bleeding tendency. *Platelets*, **2021**, 32, 701-704	3.6	
433	Prospective evaluation of two specific IgG immunoassays (HemosIL AcuStar HIT-IgG and HAT45G) for the diagnosis of heparin-induced thrombocytopenia: A Bayesian approach. *International Journal of Laboratory Hematology*, **2021**, 43, 468-476	2.5	0
432	Characterization of New Monoclonal PF4-Specific Antibodies as Useful Tools for Studies on Typical and Autoimmune Heparin-Induced Thrombocytopenia. *Thrombosis and Haemostasis*, **2021**, 121, 322-331	7	13
431	Effect of Methylene Blue Pathogen Inactivation on the Integrity of Immunoglobulin M and G. *Transfusion Medicine and Hemotherapy*, **2021**, 48, 148-153	4.2	5
430	In the Mood for a Blood Donation? Pilot Study about Momentary Mood, Satisfaction, and Return Behavior in Deferred First-Time Donors. *Transfusion Medicine and Hemotherapy*, **2021**, 48, 220-227	4.2	1
429	Functional Flow Cytometric Assay for Reliable and Convenient Heparin-Induced Thrombocytopenia Diagnosis in Daily Practice. *Biomedicines*, **2021**, 9,	4.8	2
428	Response. *Chest*, **2021**, 160, e95-e96	5.3	
427	Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. *Blood*, **2021**, 138, 1269-1277	2.2	46
426	Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. *Thrombosis Research*, **2021**, 203, 163-171	8.2	29
425	Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels. *Haematologica*, **2021**, 106, 3249-3252	6.6	1
424	Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia. *Thrombosis Research*, **2021**, 204, 40-51	8.2	30
423	Response. *Chest*, **2021**, 160, e250	5.3	
422	COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany. *Annals of Neurology*, **2021**, 90, 627-639	9.4	51
421	Acute myocardial infarction and arterial embolism in a patient with newly diagnosed renal mass: management dilemmas! A case report. *BMC Urology*, **2021**, 21, 111	2.2	
420	Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 3193-3202	15.4	3

419	Postmortem investigation of fatalities following vaccination with COVID-19 vaccines. *International Journal of Legal Medicine*, **2021**, 135, 2335-2345	3.1	10
418	Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. *Blood*, **2021**, 138, 2256-2268	2.2	67
417	Vaccine-Induced Thrombocytopenia with Severe Headache. *New England Journal of Medicine*, **2021**, 385, 2103-2105	59.2	28
416	Decline in Pathogenic Antibodies over Time in VITT. *New England Journal of Medicine*, **2021**, 385, 1815-1816	59.2	22
415	Platelet-activating anti-PF4 antibodies mimicking VITT antibodies in an unvaccinated patient with monoclonal gammopathy.. *Haematologica*, **2021**,	6.6	4
414	Pneumolysin induces platelet destruction, not platelet activation, which can be prevented by immunoglobulin preparations in vitro. *Blood Advances*, **2020**, 4, 6315-6326	7.8	9
413	Characteristics of Recipients of Red Blood Cell Concentrates in a German Federal State. *Transfusion Medicine and Hemotherapy*, **2020**, 47, 370-377	4.2	3
412	Ticagrelor causes false-negative functional tests for heparin-induced thrombocytopenia. *Blood*, **2020**, 135, 875-878	2.2	4
411	Whole-genome sequencing of a sporadic primary immunodeficiency cohort. *Nature*, **2020**, 583, 90-95	50.4	69
410	Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. *Blood*, **2020**, 136, 353-361	2.2	24
409	Label-free on chip quality assessment of cellular blood products using real-time deformability cytometry. *Lab on A Chip*, **2020**, 20, 2306-2316	7.2	9
408	Response of Human Blood Platelets on Nanoscale Groove Patterns: Implications for Platelet Storage. *ACS Applied Nano Materials*, **2020**, 3, 6996-7004	5.6	7
407	Whole-genome sequencing of patients with rare diseases in a national health system. *Nature*, **2020**, 583, 96-102	50.4	139
406	Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. *Critical Care*, **2020**, 24, 364	10.8	75
405	Actualit□ sur le diagnostic et la prise en charge des thrombop□ies induites par l□□parine. *Revue Francophone Des Laboratoires*, **2020**, 2020, 48-58	0	
404	Comparative Analysis of a French Prospective Series of 144 Patients with Heparin-Induced Thrombocytopenia (FRIGTIH) and the Literature. *Thrombosis and Haemostasis*, **2020**, 120, 1096-1107	7	15
403	Diagnosis of Inherited Platelet Disorders on a Blood Smear. *Journal of Clinical Medicine*, **2020**, 9,	5.1	19
402	Quantifying single-platelet biomechanics: An outsider's guide to biophysical methods and recent advances. *Research and Practice in Thrombosis and Haemostasis*, **2020**, 4, 386-401	5.1	8

401	Physicochemical Characteristics of Platelet Factor 4 under Various Conditions are Relevant for Heparin-Induced Thrombocytopenia Testing. *Journal of Physical Chemistry B*, **2020**, 124, 1438-1443	3.4	2
400	Activated platelets kill Staphylococcus aureus, but not Streptococcus pneumoniae-The role of FcγRIIa and platelet factor 4/heparinantibodies. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 1459-1468	15.4	7
399	In Reply. *Deutsches Ärzteblatt International*, **2020**, 117, 753	2.5	
398	Severe Hemorrhage Associated With Oral Anticoagulants. *Deutsches Ärzteblatt International*, **2020**, 117, 312-319	2.5	5
397	Characterization of the interaction between platelet factor 4 and homogeneous synthetic low molecular weight heparins. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 390-398	15.4	4
396	Transfusion in limited infrastructure locations – where to go decades after safe blood initiative by World Health Organization?. *ISBT Science Series*, **2020**, 15, 118-125	1.1	4
395	Platelet Transfusion in Perioperative Medicine. *Seminars in Thrombosis and Hemostasis*, **2020**, 46, 50-61	5.3	11
394	Novel phenotypes observed in patients with -linked leukaemia/familial thrombocytopenia syndrome and a biallelic risk allele as leukaemogenic cofactor. *Journal of Medical Genetics*, **2020**, 57, 427-433	5.8	5
393	Use of von Willebrand Factor Concentrate in Inherited von Willebrand Disease: How Often Is It Useful to Add Factor VIII?. *Transfusion Medicine Reviews*, **2020**, 34, 128-129	7.4	
392	Structure and function of the ubiquitin-proteasome system in platelets. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 771-780	15.4	15
391	The Polygenic and Monogenic Basis of Blood Traits and Diseases. *Cell*, **2020**, 182, 1214-1231.e11	56.2	96
390	Evaluation of functional assays for the diagnosis of heparin induced thrombocytopenia using 5B9, a monoclonal IgG that mimics human antibodies. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 968-975	15.4	11
389	Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia. *Journal of Clinical Medicine*, **2020**, 9,	5.1	23
388	Real-life evaluation of an automated immunoassay for diagnosis of heparin-induced thrombocytopenia. *Thrombosis Research*, **2020**, 196, 400-403	8.2	2
387	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. *Blood*, **2020**, 136, 1956-1967	2.2	15
386	Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome. *Blood Advances*, **2020**, 4, 3368-3377	7.8	4
385	Function of Large and Small Platelets Differs, Depending on Extracellular Calcium Availability and Type of Inductor. *Thrombosis and Haemostasis*, **2020**, 120, 1075-1086	7	6
384	Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. *Cell*, **2020**, 182, 1198-1213.e14	56.2	88

383	Clinical management, ethics and informed consent related to multi-gene panel-based high throughput sequencing testing for platelet disorders: Communication from the SSC of the ISTH. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 2751-2758	15.4	11
382	The impact of physiological stress conditions on protein structure and trypsin inhibition of serine protease inhibitor Kazal type 1 (SPINK1) and its N34S variant. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2020**, 1868, 140281	4	3
381	Diagnosis and management of heparin-induced thrombocytopenia. *Anaesthesia, Critical Care & Pain Medicine*, **2020**, 39, 291-310	3	30
380	Not all red cell concentrate units are equivalent: international survey of processing and in vitro quality data. *Vox Sanguinis*, **2019**, 114, 783-794	3.1	7
379	Well-being and return rate of first-time whole blood donors. *Vox Sanguinis*, **2019**, 114, 154-161	3.1	5
378	Defective Zn homeostasis in mouse and human platelets with □and □storage pool diseases. *Scientific Reports*, **2019**, 9, 8333	4.9	12
377	Reactivity of platelet-activating and nonplatelet-activating anti-PF4/heparin antibodies in enzyme immunosorbent assays under different conditions. *Journal of Thrombosis and Haemostasis*, **2019**, 17, 1113-1119	15.4	5
376	Simplifying the diagnosis of inherited platelet disorders? The new tools do not make it any easier. *Blood*, **2019**, 133, 2478-2483	2.2	17
375	Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. *British Journal of Haematology*, **2019**, 185, 549-562	4.5	31
374	Mean platelet volume is more important than age for defining reference intervals of platelet counts. *PLoS ONE*, **2019**, 14, e0213658	3.7	8
373	Postnatal intervention for the treatment of FNAIT: a systematic review. *Journal of Perinatology*, **2019**, 39, 1329-1339	3.1	11
372	Outcome of an enhanced diagnostic pipeline for patients suspected of inherited thrombocytopenia. *British Journal of Haematology*, **2019**, 186, 373-376	4.5	7
371	Role of Platelet Size Revisited-Function and Protein Composition of Large and Small Platelets. *Thrombosis and Haemostasis*, **2019**, 119, 407-420	7	22
370	Cold storage of platelets in additive solution: the impact of residual plasma in apheresis platelet concentrates. *Haematologica*, **2019**, 104, 207-214	6.6	20
369	Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT. *Blood*, **2019**, 133, 978-989	2.2	11
368	Maternal HPA-1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review. *Vox Sanguinis*, **2019**, 114, 79-94	3.1	22
367	Diagnosis of hereditary platelet disorders in the era of next-generation sequencing: "primum non nocere". *Journal of Thrombosis and Haemostasis*, **2019**, 17, 551-554	15.4	19
366	An international external quality assessment for laboratory diagnosis of heparin-induced thrombocytopenia. *Journal of Thrombosis and Haemostasis*, **2019**, 17, 525-531	15.4	18

365	Interaction between the Staphylococcus aureus extracellular adherence protein Eap and its subdomains with platelets. *International Journal of Medical Microbiology*, **2018**, 308, 683-691	3.7	6
364	High-Sensitivity Cardiac Troponin T: Association of Creatine Kinase Catalytic Activity With the 99 Percentile. *Clinical Chemistry*, **2018**, 64, 973-974	5.5	3
363	Platelets kill bacteria by bridging innate and adaptive immunity via platelet factor 4 and FcRIIA. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 1187-1197	15.4	38
362	Release of Platelet-Derived Sphingosine-1-Phosphate Involves Multidrug Resistance Protein 4 (MRP4/ABCC4) and Is Inhibited by Statins. *Thrombosis and Haemostasis*, **2018**, 118, 132-142	7	19
361	Heparininduzierte Thrombozyto penie. *Gefasschirurgie*, **2018**, 23, 193-207	0.3	1
360	Secreted Immunomodulatory Proteins of Staphylococcus aureus Activate Platelets and Induce Platelet Aggregation. *Thrombosis and Haemostasis*, **2018**, 118, 745-757	7	20
359	Toward the Relevance of Platelet Subpopulations for Transfusion Medicine. *Frontiers in Medicine*, **2018**, 5, 17	4.9	21
358	The Non-Hemostatic Aspects of Transfused Platelets. *Frontiers in Medicine*, **2018**, 5, 42	4.9	36
357	Uptake Pathways of Protein-Coated Magnetic Nanoparticles in Platelets. *ACS Applied Materials & Interfaces*, **2018**, 10, 28314-28321	9.5	7
356	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. *American Journal of Human Genetics*, **2018**, 103, 3-18	11	27
355	An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 378-388	15.4	43
354	American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. *Blood Advances*, **2018**, 2, 3360-3392	7.8	263
353	12. Gerinnungsstörungen im Rahmen des SHT **2018**, 209-220		
352	Distinct Binding Characteristics of Pathogenic Anti-Platelet Factor-4/Polyanion Antibodies to Antigens Coated on Different Substrates: A Perspective on Clinical Application. *ACS Nano*, **2018**, 12, 12030-12041	16.7	7
351	The role of social media for blood donor motivation and recruitment. *Transfusion*, **2018**, 58, 2257-2259	2.9	18
350	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. *American Journal of Human Genetics*, **2018**, 103, 144-153	11	18
349	International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy. *Vox Sanguinis*, **2018**, 113, e36	3.1	
348	Biallelic Mutation of ARHGEF18, Involved in the Determination of Epithelial Apicobasal Polarity, Causes Adult-Onset Retinal Degeneration. *American Journal of Human Genetics*, **2017**, 100, 334-342	11	14

347	Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors. *Haematologica*, **2017**, 102, 282-294	6.6	48
346	Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. *Blood*, **2017**, 129, 1538-1547	2.2	66
345	Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants: An Observational Registry Analysis. *Anesthesiology*, **2017**, 127, 111-120	4.3	40
344	Altered timing of riboflavin and ultraviolet light pathogen inactivation improves platelet in vitro quality. *Transfusion*, **2017**, 57, 2026-2034	2.9	7
343	Platelet factor 4/heparin complexes present epitopes differently on solid-phase vs platelet surfaces. *Blood*, **2017**, 129, 3498-3501	2.2	13
342	Diagnosis of inherited platelet disorders on a blood smear: a tool to facilitate worldwide diagnosis of platelet disorders. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 1511-1521	15.4	49
341	Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity. *Nature Communications*, **2017**, 8, 14945	17.4	60
340	Development of RBC transfusion indications and the collection of patient-specific pre-transfusion information. *Vox Sanguinis*, **2017**, 112, e22-e47	3.1	
339	Recessive grey platelet-like syndrome with unaffected erythropoiesis in the absence of the splice isoform GFI1B-p37. *Haematologica*, **2017**, 102, e375-e378	6.6	12
338	Emergency transfusion of patients with unknown blood type with blood group O Rhesus D positive red blood cell concentrates: a prospective, single-centre, observational study. *Lancet Haematology,the*, **2017**, 4, e218-e224	14.6	28
337	Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. *American Journal of Human Genetics*, **2017**, 100, 75-90	11	235
336	Phenotypic Characterization of Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. *Circulation*, **2017**, 136, 2022-2033	16.7	75
335	Magnetic Nanoparticle Labeling of Human Platelets from Platelet Concentrates for Recovery and Survival Studies. *ACS Applied Materials & Interfaces*, **2017**, 9, 34666-34673	9.5	11
334	Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparin-induced thrombocytopenia antibodies. *British Journal of Haematology*, **2017**, 179, 811-819	4.5	34
333	Longitudinal Changes in the Blood Supply and Demand in North-East-Germany 2005-2015. *Transfusion Medicine and Hemotherapy*, **2017**, 44, 224-231	4.2	12
332	Implementation of a rapid HIT immunoassay at a university hospital - Retrospective analysis of HIT laboratory orders in patients with thrombocytopenia. *Thrombosis Research*, **2017**, 158, 65-70	8.2	0
331	Autoimmune heparin-induced thrombocytopenia. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 2099-2114	13.4	216
330	Effect of pH and ionic strength on the binding strength of anti-PF4/polyanion antibodies. *European Biophysics Journal*, **2017**, 46, 795-801	1.9	7

329	Motivational factors for blood donation in first-time donors and repeat donors: a cross-sectional study in West Pomerania. *Transfusion Medicine*, **2017**, 27, 413-420	1.3	20
328	The 99th percentile and imprecision of point-of-care cardiac troponin I in comparison to central laboratory tests in a large reference population. *Clinical Biochemistry*, **2017**, 50, 1198-1202	3.5	5
327	Several adaptor proteins promote intracellular localisation of the transporter MRP4/ABCC4 in platelets and haematopoietic cells. *Thrombosis and Haemostasis*, **2017**, 117, 105-115	7	11
326	Idiopathic catastrophic thrombosis with happy ending. *BMJ Case Reports*, **2017**, 2017,	0.9	1
325	A population-based longitudinal study on the implication of demographic changes on blood donation and transfusion demand. *Blood Advances*, **2017**, 1, 867-874	7.8	28
324	Comparison of HapMap and 1000 Genomes Reference Panels in a Large-Scale Genome-Wide Association Study. *PLoS ONE*, **2017**, 12, e0167742	3.7	21
323	ABO blood type B and fucosyltransferase 2 non-secretor status as genetic risk factors for chronic pancreatitis. *Gut*, **2016**, 65, 353-4	19.2	12
322	Rupture Forces among Human Blood Platelets at different Degrees of Activation. *Scientific Reports*, **2016**, 6, 25402	4.9	34
321	Risk factors for heparin-induced thrombocytopenia: Focus on Fc receptors. *Thrombosis and Haemostasis*, **2016**, 116, 799-805	7	37
320	Management of heparin-induced thrombocytopenia. *Current Opinion in Hematology*, **2016**, 23, 462-70	3.3	31
319	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. *American Journal of Human Genetics*, **2016**, 99, 40-55	11	61
318	PDK1 Determines Collagen-Dependent Platelet Ca2+ Signaling and Is Critical to Development of Ischemic Stroke In Vivo. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2016**, 36, 1507-16	9.4	19
317	Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. *American Journal of Human Genetics*, **2016**, 99, 22-39	11	42
316	Thrombin generation in two families with MYH9-related platelet disorder. *Platelets*, **2016**, 27, 264-7	3.6	4
315	Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation. *Journal of Cancer Research and Clinical Oncology*, **2016**, 142, 1091-7	4.9	4
314	A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration. *Human Molecular Genetics*, **2016**, 25, 358-70	5.6	54
313	Characterization of 5B9, a Chimeric Monoclonal Anti-PF4/H Antibody with a Human Fc Fragment and Which Mimics the Effects of HIT Human Antibodies. *Blood*, **2016**, 128, 138-138	2.2	3
312	An Autosomal-Recessive GFI1B Mutation Defines the Splice Isoform p37 As Essential for Biogenesis of Functional Human Platelets, but Dispensable for Erythropoiesis. *Blood*, **2016**, 128, 2644-2644	2.2	1

311	Thrombin generation, ProC( )Global, prothrombin time and activated partial thromboplastin time in thawed plasma stored for seven days and after methylene blue/light pathogen inactivation. *Blood Transfusion*, **2016**, 14, 66-72	3.6	7
310	Acquired Thrombocytopenia **2016**, 327-349		
309	Biophysical tools to assess the interaction of PF4 with polyanions. *Thrombosis and Haemostasis*, **2016**, 116, 783-791	7	9
308	Partially desulfated heparin modulates the interaction between anti-protamine/heparin antibodies and platelets. *Thrombosis and Haemostasis*, **2016**, 115, 324-32	7	4
307	Further insights into the anti-PF4/heparin IgM immune response. *Thrombosis and Haemostasis*, **2016** , 115, 752-61	7	23
306	Assessment of human platelet survival in the NOD/SCID mouse model: technical considerations. *Transfusion*, **2016**, 56, 1370-6	2.9	7
305	Proteomic profile of platelets during reconstitution of platelet counts after apheresis. *Proteomics - Clinical Applications*, **2016**, 10, 831-8	3.1	3
304	Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. *American Journal of Human Genetics*, **2016**, 99, 8-21	11	47
303	Predonation finger lancet punctures: a potential risk factor for interdonor pathogen transmission in the blood donor clinic. *Vox Sanguinis*, **2016**, 111, 3-7	3.1	0
302	Why is one arm stronger than two arms? IgG4 antibodies in IgG4-related autoimmune pancreatitis. *Gut*, **2016**, 65, 1240-1	19.2	1
301	How I evaluate and treat thrombocytopenia in the intensive care unit patient. *Blood*, **2016**, 128, 3032-3042	12	39
300	A population-based longitudinal study on the implications of demographics on future blood supply. *Transfusion*, **2016**, 56, 2986-2994	2.9	27
299	Reversal of dabigatran by idarucizumab: when and how?. *Expert Review of Hematology*, **2016**, 9, 519-28	2.8	5
298	Impact of physical activity of individuals and creatine kinase on 99th percentiles of troponin I assays. *Clinica Chimica Acta*, **2016**, 462, 187-192	6.2	5
297	Flucloxacillin-induced immune thrombocytopenia. *Transfusion*, **2016**, 56, 67-72	2.9	3
296	Fucosyltransferase 2 (FUT2) non-secretor status and blood group B are associated with elevated serum lipase activity in asymptomatic subjects, and an increased risk for chronic pancreatitis: a genetic association study. *Gut*, **2015**, 64, 646-56	19.2	60
295	CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia. *New England Journal of Medicine*, **2015**, 373, 252-61	59.2	358
294	Tranexamic acid for treatment of bleeding in hemophagocytic lymphohistiocytosis. *Thrombosis Research*, **2015**, 135, 1037-9	8.2	2

293	Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study. *Journal of Thrombosis and Thrombolysis*, **2015**, 39, 60-7	5.1	20
292	Quantitative description of thermodynamic and kinetic properties of the platelet factor 4/heparin bonds. *Nanoscale*, **2015**, 7, 10130-9	7.7	29
291	Heparin-Induced Thrombocytopenia. *New England Journal of Medicine*, **2015**, 373, 1883-4	59.2	59
290	Mass spectrometric phosphoproteome analysis of small-sized samples of human neutrophils. *Clinica Chimica Acta*, **2015**, 451, 199-207	6.2	3
289	The transfusion-related acute lung injury controversy: lessons from heparin-induced thrombocytopenia. *Transfusion*, **2015**, 55, 1128-34	2.9	10
288	Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2. *Blood*, **2015**, 125, 2397-404	2.2	61
287	Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. *Blood*, **2015**, 125, 1180-8	2.2	74
286	Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF. *Blood*, **2015**, 126, e19-29	2.2	45
285	Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment. *American Journal of Hematology*, **2015**, 90, 675-8	7.1	48
284	Impact of priming on the response of neutrophils to human neutrophil alloantigen-3a antibodies. *Transfusion*, **2015**, 55, 1512-21	2.9	8
283	Human neutrophil antigen-3a antibodies induce neutrophil stiffening and conformational activation of CD11b without shedding of L-selectin. *Transfusion*, **2015**, 55, 2939-48	2.9	2
282	HNA antibody-mediated neutrophil aggregation is dependent on serine protease activity. *Vox Sanguinis*, **2015**, 109, 366-74	3.1	0
281	Another surprising finding in heparin-induced thrombocytopenia--eat big. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 1414-5	15.4	3
280	Polyphosphates form antigenic complexes with platelet factor 4 (PF4) and enhance PF4-binding to bacteria. *Thrombosis and Haemostasis*, **2015**, 114, 1189-98	7	30
279	A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record. *Thrombosis and Haemostasis*, **2015**, 113, 772-81	7	41
278	Reversal of anticoagulants: an overview of current developments. *Thrombosis and Haemostasis*, **2015**, 113, 931-42	7	126
277	International Validation of a Dithiothreitol (DTT)-Based Method to Resolve the Daratumumab Interference with Blood Compatibility Testing. *Blood*, **2015**, 126, 3567-3567	2.2	2
276	Hemostatic management of patients undergoing ear-nose-throat surgery. *GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery*, **2015**, 14, Doc07		2

275	In Reply. *Deutsches Ärzteblatt International*, **2015**, 112, 506	2.5	
274	Proteome changes in platelets after pathogen inactivation--an interlaboratory consensus. *Transfusion Medicine Reviews*, **2014**, 28, 72-83	7.4	63
273	Characterization of bonds formed between platelet factor 4 and negatively charged drugs using single molecule force spectroscopy. *Soft Matter*, **2014**, 10, 2775-84	3.6	13
272	Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits. *Nature Genetics*, **2014**, 46, 629-34	36.3	92
271	Amplification of bacteria-induced platelet activation is triggered by FcRIIA, integrin IIbβ3, and platelet factor 4. *Blood*, **2014**, 123, 3166-74	2.2	101
270	Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. *Blood*, **2014**, 124, 2442-9	2.2	50
269	Me or not me? The danger of spontaneity. *Blood*, **2014**, 123, 3536-8	2.2	27
268	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. *Haematologica*, **2014**, 99, 1387-94	6.6	52
267	Platelet transfusion in hematology, oncology and surgery. *Deutsches Ärzteblatt International*, **2014**, 111, 809-15	2.5	25
266	Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity. *Thrombosis and Haemostasis*, **2014**, 112, 53-64	7	50
265	Micropatterned array to assess the interaction of single platelets with platelet factor 4-heparin-IgG complexes. *Thrombosis and Haemostasis*, **2014**, 111, 862-72	7	13
264	Evaluation of a new German blood donor questionnaire. *Vox Sanguinis*, **2014**, 106, 55-60	3.1	8
263	Current insights into the laboratory diagnosis of HIT. *International Journal of Laboratory Hematology*, **2014**, 36, 296-305	2.5	34
262	Anti-platelet factor 4/heparin antibodies in patients with impaired graft function after liver transplantation. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 871-8	15.4	7
261	Cochlear implantation is safe and effective in patients with MYH9-related disease. *Orphanet Journal of Rare Diseases*, **2014**, 9, 100	4.2	22
260	Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial. *Critical Care*, **2014**, 18, 588	10.8	18
259	New insights in heparin-induced thrombocytopenia by the use of fluid-phase assays to detect specifically platelet factor 4/heparin complex antibodies and antibody-secreting cells. *Thrombosis Research*, **2014**, 134, 174-81	8.2	3
258	Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin. *Transfusion*, **2014**, 54, 640-5	2.9	26

257	Acquired hemophilia with inhibitors presenting as an emergency: misinterpretation of clotting results during direct oral anticoagulation. *Deutsches Ärzteblatt International*, **2014**, 111, 345-8	2.5	10
256	Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis. *Annals of Hematology*, **2013**, 92, 945-52	3	6
255	Thrombocytopenia in the intensive care unit-diagnostic approach and management. *Seminars in Hematology*, **2013**, 50, 239-50	4	31
254	Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. *Thrombosis Research*, **2013**, 131, e85-90	8.2	51
253	Heparin-induced thrombocytopenia. *Methods in Molecular Biology*, **2013**, 992, 301-18	1.4	3
252	Pooled platelet concentrates or apheresis platelets?. *New England Journal of Medicine*, **2013**, 368, 1849	59.2	8
251	Donor exposures in recipients of pooled platelet concentrates. *New England Journal of Medicine*, **2013**, 368, 487-9	59.2	17
250	Comparison of the 99th percentiles of three troponin I assays in a large reference population. *Clinical Chemistry and Laboratory Medicine*, **2013**, 51, 2181-6	5.9	6
249	Alternative diagnosis to heparin-induced thrombocytopenia in two critically ill patients despite a positive PF4/heparin-antibody test. *Upsala Journal of Medical Sciences*, **2013**, 118, 279-84	2.8	5
248	Expression of the CTL2 transcript variants in human peripheral blood cells and human tissues. *Transfusion*, **2013**, 53, 3217-23	2.9	12
247	Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. *Blood*, **2013**, 121, 2821-7	2.2	54
246	Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody in mice: toward targeted treatment of fetal-alloimmune thrombocytopenia. *Blood*, **2013**, 122, 321-7	2.2	33
245	Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. *Blood*, **2013**, 122, 272-81	2.2	104
244	Human neutrophil antigen-3a antibodies induce neutrophil aggregation in a plasma-free medium. *Blood Transfusion*, **2013**, 11, 541-7	3.6	4
243	Storage of thawed plasma for a liquid plasma bank: impact of temperature and methylene blue pathogen inactivation. *Transfusion*, **2012**, 52, 529-36	2.9	22
242	HIT-antibodies promote their own antigen. *Blood*, **2012**, 120, 930-1	2.2	3
241	Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. *Blood*, **2012**, 119, 1248-55	2.2	84
240	Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD. *Blood*, **2012**, 119, 3333-41	2.2	26

239	Heparin-induced thrombocytopenia: further evidence for a unique immune response. *Blood*, **2012**, 120, 4238-45	2.2	15
238	Polymorphisms of protein tyrosine phosphatase CD148 influence FcγRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia. *Blood*, **2012**, 120, 1309-16	2.2	39
237	Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. *Blood*, **2012**, 120, 3345-52	2.2	85
236	Early storage lesions in apheresis platelets are induced by the activation of the integrin αIIbβ3 and focal adhesion signaling pathways. *Journal of Proteomics*, **2012**, 76 Spec No., 297-315	3.9	30
235	Seventy-five genetic loci influencing the human red blood cell. *Nature*, **2012**, 492, 369-75	50.4	257
234	Interleukin-10 promoter microsatellite polymorphisms influence the immune response to heparin and the risk of heparin-induced thrombocytopenia. *Thrombosis Research*, **2012**, 129, 465-9	8.2	15
233	Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective. *Thrombosis Research* , **2012**, 129, 426-33	8.2	55
232	Development of a method for magnetic labeling of platelets. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2012**, 8, 537-44	6	21
231	Structural requirements for the procoagulant activity of nucleic acids. *PLoS ONE*, **2012**, 7, e50399	3.7	31
230	Management of heparin-induced thrombocytopenia. *Expert Opinion on Pharmacotherapy*, **2012**, 13, 987-1006	4	11
229	Transporters in human platelets: physiologic function and impact for pharmacotherapy. *Blood*, **2012**, 119, 3394-402	2.2	68
228	Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia. *Therapeutic Advances in Hematology*, **2012**, 3, 237-51	5.7	29
227	A patient with Fechtner syndrome successfully treated with romiplostim. *Thrombosis and Haemostasis*, **2012**, 107, 590-1	7	14
226	Advances in the treatment of heparin-induced thrombocytopenia: latest clinical data. *Clinical Investigation*, **2011**, 1, 1301-1314		1
225	New gene functions in megakaryopoiesis and platelet formation. *Nature*, **2011**, 480, 201-8	50.4	330
224	Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. *Thrombosis Research*, **2011**, 128, 256-60	8.2	30
223	Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. *Lancet, The*, **2011**, 378, 1166-73	40	115
222	Angiotensin II-dependent hypertension causes reversible changes in the platelet proteome. *Journal of Hypertension*, **2011**, 29, 2126-37	1.9	9

221	Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. *Blood*, **2011**, 117, 1370-8	2.2	164
220	Bacteria and HIT: a close connection?. *Blood*, **2011**, 117, 1105-6	2.2	
219	Platelet activation by heparin. *Blood*, **2011**, 117, 4686-7	2.2	16
218	Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. *Blood*, **2011**, 118, 1395-401	2.2	66
217	Geno- and phenotyping and immunogenicity of HNA-3. *Transfusion*, **2011**, 51, 18-24	2.9	54
216	Implications of demographics on future blood supply: a population-based cross-sectional study. *Transfusion*, **2011**, 51, 702-9	2.9	72
215	Epitope mapping of antibodies directed against the human neutrophil alloantigen 3a. *Transfusion*, **2011**, 51, 2160-7	2.9	17
214	Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). *Transfusion*, **2011**, 51, 2620-6	2.9	48
213	Immunogenic but effective: the HIT-fondaparinux brain puzzler. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 2386-8	15.4	11
212	Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 2498-500	15.4	118
211	MYH9 related platelet disorders - often unknown and misdiagnosed. *Klinische Padiatrie*, **2011**, 223, 120-5	0.9	17
210	Non-muscle myosin IIA is required for the development of the zebrafish glomerulus. *Kidney International*, **2011**, 80, 1055-63	9.9	36
209	Developments in the definition and clinical impact of human neutrophil antigens. *Current Opinion in Hematology*, **2011**, 18, 452-60	3.3	34
208	Hospital-specific calculation of heparin-induced thrombocytopenia costs: a review/Kalkulation der Kosten f□eine Heparin-induzierte Thrombozytopenie (HIT) in Krankenha□ern. *Laboratoriums Medizin*, **2011**, 35, 35-43		
207	The diagnostic value of the anti-PF4/heparin immunoassay high-dose heparin confirmatory test in cardiac surgery patients. *Anesthesia and Analgesia*, **2011**, 112, 774-6	3.9	12
206	Multiple loci are associated with white blood cell phenotypes. *PLoS Genetics*, **2011**, 7, e1002113	6	92
205	The molecular charge and size of heparins determine their impact on the decidualization of human endometrial stromal cells. *Molecular Human Reproduction*, **2011**, 17, 354-9	4.4	10
204	Fcgamma-receptor IIa polymorphism and the role of immunoadsorption in cardiac dysfunction in patients with dilated cardiomyopathy. *Clinical Pharmacology and Therapeutics*, **2010**, 87, 452-8	6.1	34

203	Characterization of the human neutrophil alloantigen-3a. *Nature Medicine*, **2010**, 16, 45-8	50.5	126
202	Coombs' crossmatch after negative antibody screening--a retrospective observational study comparing the tube test and the microcolumn technology. *Vox Sanguinis*, **2010**, 98, e269-75	3.1	6
201	Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. *Thrombosis and Haemostasis*, **2010**, 103, 145-50	7	48
200	Common variants at 10 genomic loci influence hemoglobin A(C) levels via glycemic and nonglycemic pathways. *Diabetes*, **2010**, 59, 3229-39	0.9	314
199	Potassium reference intervals for lithium-heparin plasma and serum from a population-based cohort / Kalium Referenzbereiche f Lithium-Heparin-Plasma und Serum aus einer bev lkerungsbezogenen Studie. *Laboratoriums Medizin*, **2010**, 34, 39-44		7
198	Perioperative thrombocytopenia in cardiac surgical patients - incidence of heparin-induced thrombocytopenia, morbidities and mortality. *European Journal of Cardio-thoracic Surgery*, **2010**, 37, 1391-5	3	28
197	Demographic Changes: The Impact for Safe Blood Supply. *Transfusion Medicine and Hemotherapy*, **2010**, 37, 141-148	4.2	56
196	Novel Mutation in Bernard-Soulier Syndrome. *Transfusion Medicine and Hemotherapy*, **2010**, 37, 278-284	4.2	20
195	MYH-9 Related Platelet Disorders: Strategies for Management and Diagnosis. *Transfusion Medicine and Hemotherapy*, **2010**, 37, 260-267	4.2	45
194	Thrombocytopenia in the intensive care unit patient. *Hematology American Society of Hematology Education Program*, **2010**, 2010, 135-43	3.1	107
193	Isolation of platelet granules. *Current Protocols in Cell Biology*, **2010**, Chapter 3, Unit 3.35	2.3	4
192	Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery. *American Heart Journal*, **2010**, 160, 362-9	4.9	39
191	Role of MRP4 (ABCC4) in platelet adenine nucleotide-storage: evidence from patients with delta-storage pool deficiencies. *American Journal of Pathology*, **2010**, 176, 1097-103	5.8	43
190	Expression of ABC-type transport proteins in human platelets. *Pharmacogenetics and Genomics*, **2010**, 20, 396-400	1.9	29
189	The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. *Blood*, **2010**, 115, 1797-803	2.2	122
188	Opposites attract. *Blood*, **2010**, 115, 440-1	2.2	8
187	Anucleate platelets generate progeny. *Blood*, **2010**, 115, 3801-9	2.2	125
186	The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. *Journal of Critical Care*, **2010**, 25, 287-93	4	92

185	Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. *Transfusion*, **2010**, 50, 32-9	2.9	23
184	Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 30-6	15.4	124
183	Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 504-12	15.4	39
182	Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 2025-31	15.4	55
181	Transfusion medicine and proteomics. Alliance or coexistence?. *Blood Transfusion*, **2010**, 8 Suppl 3, s16-25	3.6	1
180	Heparin-induced thrombocytopenia. *Hamostaseologie*, **2010**, 30, 17-8, 20-8	1.9	11
179	Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. *Drug Metabolism and Disposition*, **2009**, 37, 1129-37	4	53
178	Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. *Expert Opinion on Drug Safety*, **2009**, 8, 129-44	4.1	72
177	MYH9-related platelet disorders. *Seminars in Thrombosis and Hemostasis*, **2009**, 35, 189-203	5.3	156
176	Heparin-induced thrombocytopenia. *Journal of Thrombosis and Haemostasis*, **2009**, 7 Suppl 1, 9-12	15.4	95
175	Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs. *International Journal of Cancer*, **2009**, 124, 2303-11	7.5	50
174	Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. *Nature Genetics*, **2009**, 41, 1191-8	36.3	285
173	A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. *Nature Genetics*, **2009**, 41, 1182-90	36.3	433
172	Immune mechanisms in heparin-induced thrombocytopenia: no evidence for immunoglobulin M anti-idiotype antibodies. *Transfusion*, **2009**, 49, 1812-8	2.9	4
171	A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. *Transfusion*, **2009**, 49, 2612-24	2.9	119
170	The costs of heparin-induced thrombocytopenia: a patient-based cost of illness analysis. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 766-73	15.4	21
169	False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 1070-4	15.4	59
168	A genome-wide association study identifies three loci associated with mean platelet volume. *American Journal of Human Genetics*, **2009**, 84, 66-71	11	94

167	Risk factors for unfavorable clinical outcome in patients with documented heparin-induced thrombocytopenia. *Thrombosis Research*, **2009**, 124, 554-9	8.2	20
166	Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up. *American Heart Journal*, **2009**, 158, e15	4.9	2
165	Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required?. *Annals of Thoracic Surgery*, **2009**, 87, 1633-40	2.7	60
164	The temporal profile of the anti-PF4/heparin immune response. *Blood*, **2009**, 113, 4970-6	2.2	86
163	Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia. *Blood*, **2009**, 114, 1250-3	2.2	34
162	Characterization of the Human Neutrophil Alloantigen (HNA) 3a.. *Blood*, **2009**, 114, 24-24	2.2	3
161	Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. *Journal of Thrombosis and Haemostasis*, **2008**, 6, 428-35	15.4	61
160	Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. *Journal of Thrombosis and Haemostasis*, **2008**, 6, 2160-7	15.4	52
159	Postoperative complications after cardiac surgery and HIT: a word of caution. *Annals of Thoracic Surgery*, **2008**, 86, 1054-5; author reply 1055	2.7	1
158	Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. *Thrombosis Research*, **2008**, 122, 211-20	8.2	80
157	Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis. *Expert Review of Hematology*, **2008**, 1, 75-85	2.8	25
156	Contaminated heparin. *New England Journal of Medicine*, **2008**, 359, 1291-2; author reply 1293	59.2	17
155	Heparin-induced thrombocytopenia in intensive care patients. *Seminars in Thrombosis and Hemostasis*, **2008**, 34, 425-38	5.3	19
154	Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation. *Blood*, **2008**, 112, 4024-7	2.2	47
153	The direct thrombin inhibitor hirudin. *Thrombosis and Haemostasis*, **2008**, 99, 819-29	7	173
152	Bivalirudin. *Thrombosis and Haemostasis*, **2008**, 99, 830-9	7	171
151	Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*, **2008**, 133, 340S-380S	5.3	662
150	A systematic review and survey of the management of unexpected neonatal alloimmune thrombocytopenia. *Transfusion*, **2008**, 48, 92-8	2.9	7

149	The adhesion and spreading of thrombocyte vesicles on electrode surfaces. *Bioelectrochemistry*, **2008**, 74, 210-6	5.6	25
148	Fc(gamma) receptors IIa on cardiomyocytes and their potential functional relevance in dilated cardiomyopathy. *Journal of the American College of Cardiology*, **2007**, 49, 1684-92	15.1	57
147	Very severe thrombocytopenia and fragmentation hemolysis mimicking thrombotic thrombocytopenic purpura associated with a giant intracardiac vegetation infected with Staphylococcus epidermidis: role of monocyte procoagulant activity induced by bacterial supernatant. *American Journal of Hematology*, **2007**, 82, 766-71	7.1	15
146	Too many hits in HIT?. *American Journal of Hematology*, **2007**, 82, 1035-6	7.1	7
145	Profiling of alterations in platelet proteins during storage of platelet concentrates. *Transfusion*, **2007**, 47, 1221-33	2.9	93
144	Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 1666-73	15.4	185
143	Should patients be informed about the risk of heparin-induced thrombocytopenia before prolonged low-molecular-weight heparin thromboprophylaxis post-trauma/orthopedic surgery?. *European Journal of Haematology*, **2007**, 79, 187-90	3.8	6
142	Perioperative management of MYH9 hereditary macrothrombocytopenia (Fechtner syndrome). *European Journal of Haematology*, **2007**, 79, 263-8	3.8	17
141	Subfractionation and purification of intracellular granule-structures of human platelets: an improved method based on magnetic sorting. *Journal of Immunological Methods*, **2007**, 328, 89-96	2.5	16
140	Heparin-induzierte Thrombozytopenie (HIT) bei Operationen unter Verwendung der Herz-Lungen-Maschine und bei Patienten mit mechanischer Kreislaufunterstützung. *Zeitschrift Fur Herz-, Thorax- Und Gefasschirurgie*, **2007**, 21, 198-205	0.1	1
139	Heparin-induced thrombocytopenia in intensive care patients. *Critical Care Medicine*, **2007**, 35, 1165-76	1.4	144
138	So, does low-molecular-weight heparin cause less heparin-induced thrombocytopenia than unfractionated heparin or not?. *Chest*, **2007**, 132, 1108-10	5.3	15
137	IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 235-41	15.4	50
136	Proteomics of blood-based therapeutics: a promising tool for quality assurance in transfusion medicine. *BioDrugs*, **2007**, 21, 179-93	7.9	29
135	Role of Sulfated Polysaccharides in the Pathogenesis?of Heparin-Induced Thrombocytopenia. *Fundamental and Clinical Cardiology*, **2007**, 167-186		4
134	Laboratory Testing for Heparin-Induced Thrombocytopenia. *Fundamental and Clinical Cardiology*, **2007**, 227-260		16
133	Treatment of Heparin-Induced Thrombocytopenia: An Overview. *Fundamental and Clinical Cardiology*, **2007**, 283-318		6
132	Lepirudin for the Treatment of Heparin-Induced?Thrombocytopenia. *Fundamental and Clinical Cardiology*, **2007**, 345-378		2

131	Heparin-Induced Thrombocytopenia in Children. *Fundamental and Clinical Cardiology*, **2007**, 503-518		
130	Diagnosis and management of heparin-induced thrombocytopenia. *Canadian Journal of Anaesthesia* , **2006**, 53, S123-34	3	8
129	Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. *European Journal of Haematology*, **2006**, 76, 420-6	3.8	135
128	Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support. *Journal of Thoracic and Cardiovascular Surgery*, **2006**, 131, 1373-81.e4	1.5	60
127	Heparin-induced thrombocytopenia: frequency and pathogenesis. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **2006**, 35, 37-45		23
126	Staphylococcus aureus carriers neutralize superantigens by antibodies specific for their colonizing strain: a potential explanation for their improved prognosis in severe sepsis. *Journal of Infectious Diseases*, **2006**, 193, 1275-8	7	93
125	Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 2386-93	9.4	123
124	Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). *Blood*, **2006**, 107, 3761-3	2.2	137
123	Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. *Thrombosis Research*, **2006**, 117, 507-15	8.2	52
122	Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. *Thrombosis Research*, **2006**, 118, 165-76	8.2	97
121	Empfehlungen zur Thrombozytentransfusion der Thrombozyten-Arbeitsgruppe der DGTI, GTH und DGHO. *Transfusion Medicine and Hemotherapy*, **2006**, 33, 528-543	4.2	21
120	Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. *Blood*, **2006**, 108, 2937-41	2.2	206
119	Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. *Blood*, **2006**, 108, 1492-6	2.2	86
118	Proteomics as a tool for assessment of therapeutics in transfusion medicine: evaluation of prothrombin complex concentrates. *Transfusion*, **2006**, 46, 377-85	2.9	26
117	Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 759-65	15.4	730
116	Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 678-9	15.4	50
115	Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. *Blood*, **2005**, 105, 139-44	2.2	163
114	Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. *Blood*, **2005**, 106, 2921-2	2.2	81

113	Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. *Blood*, **2005**, 106, 3791-6	2.2	215
112	Unfractionated LMWH and the risk of HIT: are medical patients different?. *Blood*, **2005**, 106, 2931-2932	2.2	4
111	Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 2428-36	15.4	174
110	Management of liver transplantation in a patient with a history of heparin-induced thrombocytopenia. *Transplant International*, **2005**, 18, 664-7	3	11
109	Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. *British Journal of Haematology*, **2005**, 128, 837-41	4.5	142
108	Transfusion medicine in the era of genomics and proteomics. *Transfusion Medicine Reviews*, **2005**, 19, 288-94	7.4	15
107	Heparin-induced thrombocytopenia with a focus on children undergoing cardiac surgery. *Progress in Pediatric Cardiology*, **2005**, 21, 71-79	0.4	1
106	Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin. *American Journal of Hematology*, **2005**, 78, 188-92	7.1	14
105	Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. *Thrombosis and Haemostasis*, **2005**, 94, 132-5	7	285
104	Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. *Thrombosis and Haemostasis*, **2005**, 94, 958-64	7	108
103	Heparininduzierte Thrombozytopenie in der Intensivmedizin. *Intensivmedizin Up2date*, **2005**, 1, 329-341	0.1	3
102	Thrombosis of the cerebral veins and sinuses. *New England Journal of Medicine*, **2005**, 353, 314-5	59.2	20
101	Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. *Thrombosis and Haemostasis*, **2004**, 91, 719-24	7	74
100	The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia. *Seminars in Thrombosis and Hemostasis*, **2004**, 30, 315-27	5.3	25
99	The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. *Blood*, **2004**, 104, 3603-10	2.2	152
98	egc-Encoded superantigens from Staphylococcus aureus are neutralized by human sera much less efficiently than are classical staphylococcal enterotoxins or toxic shock syndrome toxin. *Infection and Immunity*, **2004**, 72, 4061-71	3.7	110
97	Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*, **2004**, 126, 311S-337S	5.3	612
96	Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells. *Transfusion*, **2004**, 44, 1033-40	2.9	39

95	Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy. *Expert Review of Cardiovascular Therapy*, **2004**, 2, 339-57	2.5	27
94	Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. *Blood*, **2004**, 103, 613-6	2.2	47
93	Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. *Blood*, **2004**, 104, 3072-7	2.2	106
92	Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. *Circulation*, **2003**, 108, 2062-5	16.7	183
91	Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. *Pharmacogenetics and Genomics*, **2003**, 13, 253-8		30
90	Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. *Blood*, **2003**, 101, 2617-9	2.2	57
89	Treatment options for heparin-induced thrombocytopenia. *American Journal of Health-System Pharmacy*, **2003**, 60 Suppl 5, S12-8	2.2	6
88	Heparininduzierte Thrombozytopenie in der Pdiatrie und ihre Therapiealternativen. *Monatsschrift Fur Kinderheilkunde*, **2003**, 151, 1180-1187	0.2	4
87	MYH9 spectrum of autosomal-dominant giant platelet syndromes: unexpected association with fibulin-1 variant-D inactivation. *American Journal of Hematology*, **2003**, 74, 254-62	7.1	20
86	Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. *British Journal of Haematology*, **2003**, 121, 786-92	4.5	68
85	Benefit and risk of heparin for maintaining peripheral venous catheters in neonates: a placebo-controlled trial. *Journal of Pediatrics*, **2003**, 143, 741-5	3.6	58
84	Heparin-induced thrombocytopenia and cardiac surgery. *Annals of Thoracic Surgery*, **2003**, 76, 2121-31	2.7	584
83	Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. *Annals of Thoracic Surgery*, **2003**, 75, 577-9	2.7	30
82	Heparin-induced thrombocytopenia and cardiac surgery. *Annals of Thoracic Surgery*, **2003**, 76, 638-48	2.7	102
81	Iron deficiency anaemia in young women. *European Journal of Haematology*, **2002**, 68, 341-4	3.8	3
80	The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. *British Journal of Haematology*, **2002**, 116, 887-91	4.5	65
79	Hirudin in heparin-induced thrombocytopenia. *Seminars in Thrombosis and Hemostasis*, **2002**, 28, 431-8	5.3	21
78	Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. *Chest*, **2002**, 122, 37-42	5.3	148

77	A variant of the Sebastian platelet syndrome with unique neutrophil inclusions. *Platelets*, **2002**, 13, 121-7	3.6	8
76	Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. *Blood*, **2001**, 97, 3300-2	2.2	158
75	Drug-induced and drug-dependent immune thrombocytopenias. *Reviews in Clinical and Experimental Hematology*, **2001**, 5, 166-200; discussion 311-2		38
74	Glucosamine sulfate does not crossreact with the antibodies of patients with heparin-induced thrombocytopenia. *European Journal of Haematology*, **2001**, 66, 195-9	3.8	7
73	Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. *American Journal of Human Genetics*, **2001**, 69, 1033-45	11	250
72	Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin. *Annals of Thoracic Surgery*, **2001**, 71, 1041-2	2.7	27
71	Recombinant hirudin in clinical practice: focus on lepirudin. *Circulation*, **2001**, 103, 1479-84	16.7	124
70	Drugs for the prevention and treatment of thrombosis in patients with heparin-induced thrombocytopenia. *American Journal of Cardiovascular Drugs*, **2001**, 1, 429-43	4	13
69	A Comparison of Danaparoid and Lepirudin in Heparin-induced Thrombocytopenia. *Thrombosis and Haemostasis*, **2001**, 85, 950-957	7	136
68	Low-dose danaparoid sodium catheter flushes in an intensive care infant suffering from heparin-induced thrombocytopenia. *Pediatric Critical Care Medicine*, **2001**, 2, 175-177	3	19
67	A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. *Thrombosis and Haemostasis*, **2001**, 85, 950-7	7	22
66	Heparin-induced thrombocytopenia (HIT): in vitro and in vivo cross-reactivity to danaparoid sodium and successful treatment with recombinant hirudin (lepirudin). *European Journal of Haematology*, **2000**, 65, 148-9	3.8	6
65	Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin. *Journal of Thrombosis and Thrombolysis*, **2000**, 10 Suppl 1, 47-57	5.1	17
64	Autosomal-dominant giant platelet syndromes: a hint of the same genetic defect as in Fechtner syndrome owing to a similar genetic linkage to chromosome 22q11-13. *Blood*, **2000**, 96, 3447-3451	2.2	45
63	Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. *Blood*, **2000**, 96, 846-851	2.2	294
62	Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. *Blood*, **2000**, 96, 2373-2378	2.2	185
61	Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia. Report of four cases and review of literature. *Thrombosis Research*, **2000**, 100, 115-25	2.2	52
60	Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin. *BioDrugs*, **2000**, 14, 109-25	7.9	17

59	Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. *Blood*, **2000**, 96, 846-851	2.2	9
58	Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. *Blood*, **2000**, 96, 2373-2378	2.2	1
57	Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. *Blood*, **2000**, 96, 846-51	2.2	60
56	Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. *Blood*, **2000**, 96, 2373-8	2.2	29
55	First Workshop for Detection of Heparin-induced Antibodies: Validation of the Heparin-induced Platelet-activation Test (HIPA) in Comparison with a PF4/Heparin ELISA. *Thrombosis and Haemostasis*, **1999**, 81, 625-629	7	137
54	The ?2 Gene Coding Sequence T807/A873 of the Platelet Collagen Receptor Integrin ?2? Might Be a Genetic Risk Factor for the Development of Stroke in Younger Patients. *Blood*, **1999**, 93, 3583-3586	2.2	176
53	Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. *Circulation*, **1999**, 99, 2530-6	16.7	276
52	Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. *Circulation*, **1999**, 100, 587-93	16.7	299
51	Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. *Circulation*, **1999**, 99, 73-80	16.7	431
50	Successful thrombolysis of right atrial and ventricle thrombi encircling a temporary pacemaker lead in a patient with heparin-induced thrombocytopenia type II. *PACE - Pacing and Clinical Electrophysiology*, **1999**, 22, 678-81	1.6	15
49	Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium. *European Journal of Pediatrics*, **1999**, 158 Suppl 3, S130-3	4.1	58
48	Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. *American Journal of Clinical Pathology*, **1999**, 111, 700-6	1.9	168
47	Treatment of Heparin-Induced Thrombocytopenia. *Thrombosis and Haemostasis*, **1999**, 82, 457-467	7	31
46	The ?2 Gene Coding Sequence T807/A873 of the Platelet Collagen Receptor Integrin ?2? Might Be a Genetic Risk Factor for the Development of Stroke in Younger Patients. *Blood*, **1999**, 93, 3583-3586	2.2	2
45	First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. *Thrombosis and Haemostasis* , **1999**, 81, 625-9	7	21
44	Treatment of heparin-induced thrombocytopenia. *Thrombosis and Haemostasis*, **1999**, 82, 457-67	7	7
43	Heparin-induced thrombocytopenia: pathophysiology and clinical concerns. *Best Practice and Research: Clinical Haematology*, **1998**, 11, 461-74		3
42	Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with ultra-low-dose rt-PA lysis and recombinant hirudin (Lepirudin). *Blood Coagulation and Fibrinolysis*, **1998**, 9, 273-7	1	17

41	Adenosine Diphosphate (ADP) and ADP Receptor Play a Major Role in Platelet Activation/Aggregation Induced by Sera From Heparin-Induced Thrombocytopenia Patients. *Blood*, **1998**, 91, 549-554	2.2	78
40	Heparin-Induced Thrombocytopenia: New Insights Into the Impact of the FcRIIa-R-H131 Polymorphism. *Blood*, **1998**, 92, 1526-1531	2.2	157
39	Heparin-induced Thrombocytopenia: Towards Consensus. *Thrombosis and Haemostasis*, **1998**, 79, 1-7	7	517
38	Adenosine Diphosphate (ADP) and ADP Receptor Play a Major Role in Platelet Activation/Aggregation Induced by Sera From Heparin-Induced Thrombocytopenia Patients. *Blood*, **1998**, 91, 549-554	2.2	
37	Heparin-induced thrombocytopenia: towards consensus. *Thrombosis and Haemostasis*, **1998**, 79, 1-7	7	57
36	Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia. *Nephrology Dialysis Transplantation*, **1997**, 12, 2750-5	4.3	22
35	Recombinant hirudin is a heparin alternative in cardiac surgery. *Journal of Cardiothoracic and Vascular Anesthesia*, **1997**, 11, 538-9	2.1	8
34	Erfolgreiche Behandlung einer Heparin-induzierten Thrombo- zytopenie Typ II im Kindesalter mit rekombinantem Hirudin Fallbericht und Literaturübersicht. *Monatsschrift Fur Kinderheilkunde*, **1997**, 145, 606-612	0.2	23
33	Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. *Stroke*, **1997**, 28, 1392-5	6.7	82
32	Monitoring of r-Hirudin Anticoagulation during Cardiopulmonary Bypass Assessment of the Whole Blood Ecarin Clotting Time. *Thrombosis and Haemostasis*, **1997**, 77, 0920-0925	7	129
31	Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time. *Thrombosis and Haemostasis*, **1997**, 77, 920-5	7	27
30	Platelets of patients with peripheral arterial disease are hypersensitive to heparin. *Thrombosis Research*, **1996**, 81, 641-9	8.2	32
29	A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery. *European Journal of Cardio-thoracic Surgery*, **1996**, 10, 386-8	3	34
28	Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis. *Seminars in Thrombosis and Hemostasis*, **1995**, 21, 106-16	5.3	266
27	Characterization of the Structural Requirements for a Carbohydrate Based Anticoagulant with a Reduced Risk of Inducing the Immunological Type of Heparin-associated Thrombocytopenia. *Thrombosis and Haemostasis*, **1995**, 74, 886-892	7	104
26	Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. *Transfusion*, **1994**, 34, 381-5	2.9	202
25	Platelet response to vascular surgery--a preliminary study on the effect of aspirin and heparin. *Thrombosis Research*, **1994**, 76, 79-87	8.2	15
24	Heparin-associated thrombocytopenia: the effects of various intravenous IgG preparations on antibody mediated platelet activation--a possible new indication for high dose i.v. IgG. *Thrombosis and Haemostasis*, **1994**, 71, 641-5	7	13

23	Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. *Thrombosis and Haemostasis*, **1994**, 71, 247-51	7	305
22	Crossreactivity Studies between Sera of Patients with Heparin Associated Thrombocytopenia and a New Low Molecular Weight Heparin, Reviparin. *Thrombosis and Haemostasis*, **1994**, 72, 644-645	7	14
21	Heparin-associated thrombocytopenia: no association of immune response with HLA. *Vox Sanguinis*, **1993**, 65, 151-3	3.1	9
20	Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. *British Journal of Haematology*, **1993**, 84, 711-6	4.5	70
19	Evidence that DDAVP transiently improves hemostasis in Bernard-Soulier syndrome independent of von Willebrand-factor. *Annals of Hematology*, **1993**, 67, 149-50	3	22
18	Pregnancy complicated by heparin associated thrombocytopenia: management by a prospectively in vitro selected heparinoid (Org 10172). *Thrombosis Research*, **1993**, 71, 123-6	8.2	73
17	Heparin-associated thrombocytopenia type II in a patient with end-stage renal disease: successful anticoagulation with the low-molecular-weight heparinoid Org 10172 during haemodialysis. *Nephrology Dialysis Transplantation*, **1993**, 8, 1176-7	4.3	12
16	Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins. *Annals of Hematology*, **1992**, 64, 40-2	3	24
15	May-Hegglin anomaly: a rare cause of thrombocytopenia. *European Journal of Pediatrics*, **1992**, 151, 668-71	4.1	12
14	Heparin-associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate: evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan. *British Journal of Haematology*, **1992**, 81, 252-4	4.5	63
13	Heparin-associated thrombocytopenia: the antibody is not heparin specific. *Thrombosis and Haemostasis*, **1992**, 67, 545-9	7	24
12	Heparin-Associated Thrombocytopenia: The Antibody Is Not Heparin Specific. *Thrombosis and Haemostasis*, **1992**, 67, 545-549	7	139
11	A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. *Thrombosis and Haemostasis*, **1991**, 66, 734-6	7	42
10	A Rapid and Sensitive Test for Diagnosing Heparin-Associated Thrombocytopenia. *Thrombosis and Haemostasis*, **1991**, 66, 734-736	7	250
9	Hereditary types of thrombocytopenia with giant platelets and inclusion bodies in the leukocytes. *Blut*, **1990**, 60, 53-60		52
8	Sebastian platelet syndrome: a new variant of hereditary macrothrombocytopenia with leukocyte inclusions. *Blut*, **1990**, 61, 282-8		78
7	Plasma Isoagglutinin Depletion for Blood Group Independent Plasma Transfusion. *Transfusion Medicine and Hemotherapy*,1-7	4.2	
6	Foudroyant cerebral venous (sinus) thrombosis triggered through CLEC-2 and GPIIb/IIIa dependent platelet activation		2

5	The Polygenic and Monogenic Basis of Blood Traits and Diseases	3
4	Platelet Proteomics in Transfusion Medicine321-340	
3	COVID-19 vaccine-associated cerebral venous thrombosis in Germany	15
2	A Cross-Sectional Study of Blood Donors Psychological Characteristics over 8 Weeks. *Transfusion Medicine and Hemotherapy*,1-8	4.2
1	Risk of Blood Bag Lesions Induced by Standard Transfusion Devices. *Transfusion Medicine and Hemotherapy*,1-2	4.2